223 related articles for article (PubMed ID: 30986062)
21. Discovery of New SIRT2 Inhibitors by Utilizing a Consensus Docking/Scoring Strategy and Structure-Activity Relationship Analysis.
Huang S; Song C; Wang X; Zhang G; Wang Y; Jiang X; Sun Q; Huang L; Xiang R; Hu Y; Li L; Yang S
J Chem Inf Model; 2017 Apr; 57(4):669-679. PubMed ID: 28301150
[TBL] [Abstract][Full Text] [Related]
22. Identification of Diketopiperazine-Containing 2-Anilinobenzamides as Potent Sirtuin 2 (SIRT2)-Selective Inhibitors Targeting the "Selectivity Pocket", Substrate-Binding Site, and NAD
Mellini P; Itoh Y; Elboray EE; Tsumoto H; Li Y; Suzuki M; Takahashi Y; Tojo T; Kurohara T; Miyake Y; Miura Y; Kitao Y; Kotoku M; Iida T; Suzuki T
J Med Chem; 2019 Jun; 62(12):5844-5862. PubMed ID: 31144814
[TBL] [Abstract][Full Text] [Related]
23. SIRT2 mediated antitumor effects of shikonin on metastatic colorectal cancer.
Zhang LL; Zhan L; Jin YD; Min ZL; Wei C; Wang Q; Chen YJ; Wu QM; Hu XM; Yuan Q
Eur J Pharmacol; 2017 Feb; 797():1-8. PubMed ID: 28088387
[TBL] [Abstract][Full Text] [Related]
24. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis.
Koca İ; Özgür A; Er M; Gümüş M; Açikalin Coşkun K; Tutar Y
Eur J Med Chem; 2016 Oct; 122():280-290. PubMed ID: 27376491
[TBL] [Abstract][Full Text] [Related]
25. A Glycoconjugated SIRT2 Inhibitor with Aqueous Solubility Allows Structure-Based Design of SIRT2 Inhibitors.
Hong JY; Price IR; Bai JJ; Lin H
ACS Chem Biol; 2019 Aug; 14(8):1802-1810. PubMed ID: 31373792
[TBL] [Abstract][Full Text] [Related]
26. The discovery of a highly selective 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one SIRT2 inhibitor that is neuroprotective in an in vitro Parkinson's disease model.
Di Fruscia P; Zacharioudakis E; Liu C; Moniot S; Laohasinnarong S; Khongkow M; Harrison IF; Koltsida K; Reynolds CR; Schmidtkunz K; Jung M; Chapman KL; Steegborn C; Dexter DT; Sternberg MJ; Lam EW; Fuchter MJ
ChemMedChem; 2015 Jan; 10(1):69-82. PubMed ID: 25395356
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and structure-activity relationships of N-benzyl-N-(X-2-hydroxybenzyl)-N'-phenylureas and thioureas as antitumor agents.
Li HQ; Yan T; Yang Y; Shi L; Zhou CF; Zhu HL
Bioorg Med Chem; 2010 Jan; 18(1):305-13. PubMed ID: 19914837
[TBL] [Abstract][Full Text] [Related]
28. Novel small molecule SIRT2 inhibitors induce cell death in leukemic cell lines.
Kozako T; Mellini P; Ohsugi T; Aikawa A; Uchida YI; Honda SI; Suzuki T
BMC Cancer; 2018 Aug; 18(1):791. PubMed ID: 30081901
[TBL] [Abstract][Full Text] [Related]
29. Novel Thiourea Derivatives Bearing Sulfonamide Moiety as Anticancer Agents Through COX-2 Inhibition.
Ghorab MM; El-Gaby MSA; Alsaid MS; Elshaier YAMM; Soliman AM; El-Senduny FF; Badria FA; Sherif AYA
Anticancer Agents Med Chem; 2017; 17(10):1411-1425. PubMed ID: 28356021
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxicity and cell death mechanisms induced by a novel bisnaphthalimidopropyl derivative against the NCI-H460 non-small lung cancer cell line.
Lima RT; Barron GA; Grabowska JA; Bermano G; Kaur S; Roy N; Vasconcelos MH; Lin PK
Anticancer Agents Med Chem; 2013 Mar; 13(3):414-21. PubMed ID: 23092269
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents.
Ma LY; Zheng YC; Wang SQ; Wang B; Wang ZR; Pang LP; Zhang M; Wang JW; Ding L; Li J; Wang C; Hu B; Liu Y; Zhang XD; Wang JJ; Wang ZJ; Zhao W; Liu HM
J Med Chem; 2015 Feb; 58(4):1705-16. PubMed ID: 25610955
[TBL] [Abstract][Full Text] [Related]
32. Discovery of salermide-related sirtuin inhibitors: binding mode studies and antiproliferative effects in cancer cells including cancer stem cells.
Rotili D; Tarantino D; Nebbioso A; Paolini C; Huidobro C; Lara E; Mellini P; Lenoci A; Pezzi R; Botta G; Lahtela-Kakkonen M; Poso A; Steinkühler C; Gallinari P; De Maria R; Fraga M; Esteller M; Altucci L; Mai A
J Med Chem; 2012 Dec; 55(24):10937-47. PubMed ID: 23189967
[TBL] [Abstract][Full Text] [Related]
33. 3-(N-arylsulfamoyl)benzamides, inhibitors of human sirtuin type 2 (SIRT2).
Choi SH; Quinti L; Kazantsev AG; Silverman RB
Bioorg Med Chem Lett; 2012 Apr; 22(8):2789-93. PubMed ID: 22446090
[TBL] [Abstract][Full Text] [Related]
34. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
35. Chroman-4-one- and chromone-based sirtuin 2 inhibitors with antiproliferative properties in cancer cells.
Seifert T; Malo M; Kokkola T; Engen K; Fridén-Saxin M; Wallén EA; Lahtela-Kakkonen M; Jarho EM; Luthman K
J Med Chem; 2014 Dec; 57(23):9870-88. PubMed ID: 25383691
[TBL] [Abstract][Full Text] [Related]
36. Identification of a novel small molecule that inhibits deacetylase but not defatty-acylase reaction catalysed by SIRT2.
Kudo N; Ito A; Arata M; Nakata A; Yoshida M
Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685974
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.
Suzuki T; Khan MN; Sawada H; Imai E; Itoh Y; Yamatsuta K; Tokuda N; Takeuchi J; Seko T; Nakagawa H; Miyata N
J Med Chem; 2012 Jun; 55(12):5760-73. PubMed ID: 22642300
[TBL] [Abstract][Full Text] [Related]
38. Recent Progress on the Discovery of Sirt2 Inhibitors for the Treatment of Various Cancers.
Wang T; Xu Z; Lu Y; Shi J; Liu W; Zhang C; Jiang Z; Qi B; Bai L
Curr Top Med Chem; 2019; 19(12):1051-1058. PubMed ID: 31074370
[TBL] [Abstract][Full Text] [Related]
39. One-pot synthesis of podophyllotoxin-thiourea congeners by employing NH₂SO₃H/NaI: Anticancer activity, DNA topoisomerase-II inhibition, and apoptosis inducing agents.
Shankaraiah N; Kumar NP; Amula SB; Nekkanti S; Jeengar MK; Naidu VG; Reddy TS; Kamal A
Bioorg Med Chem Lett; 2015 Oct; 25(19):4239-44. PubMed ID: 26292628
[TBL] [Abstract][Full Text] [Related]
40. High-Throughput Screening Identifies Ascorbyl Palmitate as a SIRT2 Deacetylase and Defatty-Acylase Inhibitor.
Hong JY; Cassel J; Yang J; Lin H; Weiser BP
ChemMedChem; 2021 Nov; 16(22):3484-3494. PubMed ID: 34382754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
